Article Text

Download PDFPDF
Review: lipid lowering drugs decrease coronary artery disease (CAD) events but not all cause or CAD mortality in men with no history of CAD

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients with no history of coronary artery disease (CAD), does a lipid lowering drug (cholestyramine, gemfibrozil, pravastatin, or lovastatin) decrease the risk for CAD events, CAD mortality, or all cause mortality?

Data sources

English language studies were identified by searching Medline (1994 to June 1999) with the Medical Subject Headings (MeSH) hyperlidemia and anti cholesterolemic agents and with MeSH or keywords identifying randomised controlled trials and individual drug names, the Cochrane Clinical Trials Registry, and bibliographies of systematic reviews and clinical practice guidelines.

Study selection

Randomised controlled trials were selected if they had ≥1 year of duration and measured CAD events, CAD mortality, and all cause mortality. Exclusion criteria were studies of secondary prevention or studies published in abstract form …

View Full Text


  • Source of funding: Agency for Healthcare Research and Quality.

  • For correspondence: Dr M Pignone, Division of General Internal Medicine, 5039 Old Clinic Building, University of North Carolina, Chapel Hill, NC 27599-7110, USA. Fax + 1 919 966 2274.